98 related articles for article (PubMed ID: 19548171)
1. Efficacy of voriconazole in Japanese quail (Coturnix japonica) experimentally infected with Aspergillus fumigatus.
Tell LA; Clemons KV; Kline Y; Woods L; Kass PH; Martinez M; Stevens DA
Med Mycol; 2010 Mar; 48(2):234-44. PubMed ID: 19548171
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2013 Jan; 57(1):303-8. PubMed ID: 23114773
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis.
MacCallum DM; Whyte JA; Odds FC
Antimicrob Agents Chemother; 2005 Sep; 49(9):3697-701. PubMed ID: 16127042
[TBL] [Abstract][Full Text] [Related]
4. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Krishnan-Natesan S; Wu W; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of voriconazole against invasive pulmonary aspergillosis in a guinea-pig model.
Chandrasekar PH; Cutright J; Manavathu E
J Antimicrob Chemother; 2000 May; 45(5):673-6. PubMed ID: 10797091
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
Krishnan-Natesan S; Chandrasekar PH; Alangaden GJ; Manavathu EK
Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
[TBL] [Abstract][Full Text] [Related]
7. Anti-infectious activity of intravitreal injectable voriconazole microspheres on experimental rabbit fungal endophthalmitis caused by Aspergillus fumigatus.
Xiang-Gen W; Li-Na Y; Meng X; Hao-Ran J
J Pharm Sci; 2011 May; 100(5):1745-59. PubMed ID: 21374612
[TBL] [Abstract][Full Text] [Related]
8. Voriconazole concentrations in synovial fluid and bone tissues.
Denes E; Boumediene A; Durox H; Oksman A; Saint-Marcoux F; Darde ML; Gaulier JM
J Antimicrob Chemother; 2007 Apr; 59(4):818-9. PubMed ID: 17329266
[No Abstract] [Full Text] [Related]
9. Intravitreally implantable voriconazole delivery system for experimental fungal endophthalmitis.
Yang L; Dong X; Wu X; Xie L; Min X
Retina; 2011 Oct; 31(9):1791-800. PubMed ID: 21606889
[TBL] [Abstract][Full Text] [Related]
10. Polyhexamethylene biguanide and calcineurin inhibitors as novel antifungal treatments for Aspergillus keratitis.
Rebong RA; Santaella RM; Goldhagen BE; Majka CP; Perfect JR; Steinbach WJ; Afshari NA
Invest Ophthalmol Vis Sci; 2011 Sep; 52(10):7309-15. PubMed ID: 21849421
[TBL] [Abstract][Full Text] [Related]
11. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis.
Lamaris GA; Ben-Ami R; Lewis RE; Kontoyiannis DP
J Antimicrob Chemother; 2008 Sep; 62(3):539-42. PubMed ID: 18544603
[TBL] [Abstract][Full Text] [Related]
12. Assessment of carvacrol for control of avian aspergillosis in intratracheally challenged chickens in comparison to voriconazole with a reference on economic impact.
Tartor YH; Hassan FAM
J Appl Microbiol; 2017 Nov; 123(5):1088-1099. PubMed ID: 28795522
[TBL] [Abstract][Full Text] [Related]
13. Designing a treatment protocol with voriconazole to eliminate Aspergillus fumigatus from experimentally inoculated pigeons.
Beernaert LA; Pasmans F; Baert K; Van Waeyenberghe L; Chiers K; Haesebrouck F; Martel A
Vet Microbiol; 2009 Nov; 139(3-4):393-7. PubMed ID: 19574001
[TBL] [Abstract][Full Text] [Related]
14. Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis.
Mavridou E; Bruggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2010 Nov; 54(11):4758-64. PubMed ID: 20733046
[TBL] [Abstract][Full Text] [Related]
15. Utilization of omeprazole to augment subtherapeutic voriconazole concentrations for treatment of Aspergillus infections.
Boyd NK; Zoellner CL; Swancutt MA; Bhavan KP
Antimicrob Agents Chemother; 2012 Nov; 56(11):6001-2. PubMed ID: 22890768
[TBL] [Abstract][Full Text] [Related]
16. A model for treating avian aspergillosis: serum and lung tissue kinetics for Japanese quail (Coturnix japonica) following single and multiple aerosol exposures of a nanoparticulate itraconazole suspension.
Rundfeldt C; Wyska E; Steckel H; Witkowski A; Jeżewska-Witkowska G; Wlaź P
Med Mycol; 2013 Nov; 51(8):800-10. PubMed ID: 23815436
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.
George D; Miniter P; Andriole VT
Antimicrob Agents Chemother; 1996 Jan; 40(1):86-91. PubMed ID: 8787885
[TBL] [Abstract][Full Text] [Related]
18. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model.
Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y
Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551
[TBL] [Abstract][Full Text] [Related]
19. [Anti-infectious activity of intravitreal injectable voriconazole microspheres on experimental rabbit fungal endophthalmitis of Aspergillus fumigatus].
Yang LN; Xin M; Wu XG; Jiang HR
Yao Xue Xue Bao; 2010 Jun; 45(6):778-84. PubMed ID: 20939190
[TBL] [Abstract][Full Text] [Related]
20. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia.
Petraitiene R; Petraitis V; Groll AH; Sein T; Piscitelli S; Candelario M; Field-Ridley A; Avila N; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 2001 Mar; 45(3):857-69. PubMed ID: 11181372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
